Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found.
GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.
British pharmaceutical firm GSK announced that it will stop selling its blood cancer drug Blenrep in the United States. The company announced on Nov. 22 that it has begun the process to withdraw [.]
GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, representing the latest in a series of setbacks for the Briti..